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Velocardiofacial syndrome, conotruncal congenital heart
disease and DiGeorge syndrome present different
aspects of the same clinical situation, but congenital
heart disease is common to them all [1]. Other defects
found in these syndromes include abnormal facies,
thymic hypoplasia, cleft palate, and hypocalcemia. 
A deletion at chromosome 22q11 is the second most
common chromosomal defect detected in patients with
congenital heart disease. Although familial inheritance
occurs, most cases are sporadic [2].
A patient aged 29 years, gravida 2, para 1, presented
to our outpatient clinic with an initial diagnosis of poly-
hydramnios at the 33rd week of gestation. Her medical
history revealed that her first delivery was at term by
cesarean section, but the baby died in infancy of cyan-
otic heart disease, diffuse bronchopulmonary disease,
and infection.
Postmortem genetic investigation revealed that the
neonate had a 22q11 deletion, with associated cardio-
vascular anomalies. The parents were genetically normal.
Obstetric examination determined that the patient
was at 33 weeks of gestation, and fetal biometric meas-
urements suggested a gestational age of 31–32 weeks.
The amniotic index was 18 cm and mild polyhydramnios
was detected. Systematic ultrasonographic investigation
revealed a ventricular septal defect, a secundum-type
atrial septal defect, pulmonary atresia, and an anomaly
of the overriding aorta. These findings were interpreted
as components of tetralogy of Fallot (TOF). The patient
had not attended the hospital for prenatal screening
during her second trimester. Cordocentesis was per-
formed for prenatal diagnosis. The cytogenetic analysis
was evaluated as normal, but considering the clinical
findings and the patient’s prior history, locus-specific
fluorescence in situ hybridization (FISH) was planned
to detect possible DiGeorge syndrome. A Tuple1-Hira
FISH probe (Vysis; Abbott Laboratories, Abbott Park,
IL, USA) was used and a heterozygous deletion was
detected at 22q11.2 (Figure). Genetic counseling was
given to the family, and the patient was followed up
until the 38th week of gestation. The same chromosomal
defect had been present in the previous infant, while
the parental chromosomal structures were normal. 
A second de novo mutation was thought to be responsible
for the development of the syndrome in this case. 
A pediatric cardiologist and a pediatric surgeon assisted
at delivery by cesarean section, and the baby, who
weighed 3,000 g, was transferred to the neonatal care
unit. Biochemical analysis and echocardiographic inves-
tigations were carried out postpartum and DiGeorge
syndrome was diagnosed.
Prenatal diagnosis is essential, especially in patients
that have had previous pregnancies involving chromo-
somal defects, even those due to spontaneous muta-
tions. Counseling should be provided, and the parents
should be referred to an appropriate center.
22q11 deletion is the second most commonly seen
chromosomal defect in congenital heart diseases after
Down syndrome. It is observed in 1/4000 births on
average [3]. Cardiovascular anomalies are reported in
83% of cases with 22q11 deletion [4]. These anomalies
frequently include the conotruncal region, and patients
present with TOF. TOF is responsible for 10% of cyanotic
heart disease observed in infancy. In parallel with the
PRENATAL DIAGNOSIS OF DIGEORGE SYNDROME
Ümit Göktolga, Kazım Gezginç*, S. Temel Ceyhan, Ulas¸ Fidan, Ali Ergün, 
Muhterem Bahçe1, l˙skender Bas¸er
Departments of Obstetrics and Gynecology, and 1Genetics, 
Gulhane Military Medical Academy, Ankara, Turkey.
*Correspondence to: Dr Kazım Gezginç, Department
of Obstetrics and Gynecology, Gulhane Military
Medical Academy, 06018 Etlik, Ankara, Turkey.
E-mail: kazimgezginc@hotmail.com
Accepted: May 26, 2008
Figure. The fluorescence in situ hybridization result of 
cordocentesis material.
developments in ultrasonography, the prenatal diagnosis
of cardiac defects has increased and diagnosed cases
are followed up closely. If the detected defect is fatal,
pregnancy termination can be planned after consulta-
tion with appropriate clinics, such as pediatric surgery
and genetics. If the pregnancy is beyond the termination
limit, it is important that patients are referred to a clinic
with a pediatric cardiologist and a surgeon, where
neonatal care can be given.
Only 8% of 22q11 deletion cases are inherited, while
most develop by de novo mutation [3]. Even if one of 
the parents is affected, they may not be symptomatic,
and the chromosomal inheritance rate from a geneti-
cally affected person is only 50%. If a 22q11 deletion 
is detected prenatally in a fetus with a cardiovascular
disorder diagnosed through ultrasonography, then ge-
netic investigation of the parents should be performed.
Phenotypic abnormalities associated with the chro-
mosome 22q11.2 deletion syndrome include thymus
and parathyroid hypoplasia or aplasia, cardiac out-
flow tract abnormalities, cleft palate, velopharyngeal
insufficiency, and dysmorphic facial features. The pha-
ryngeal arches and pouches are a common embryonic
precursor for the thymus, parathyroid, and conotrun-
cal region of the heart. Defects in these organs can be
caused by impaired migration of neural crest cells into
the pouch endoderm. The phenotype of chromosome
22q11.2 deletion syndrome is very variable and the extent
of the deletion does not seem to correlate with disease
severity, thus identifying a single gene responsible for
all the phenotypic features is difficult [5].
The clinical findings associated with 22q11.2 dele-
tion are highly variable. Approximately 75% of patients
with 22q11 deletion are born with congenital heart
defects, mainly of the cardiac outflow tract and aortic
arch. Other common features include a characteristic
facial appearance, immunodeficiency from thymic hypo-
plasia, velopharyngeal dysfunction with or without cleft
palate, hypocalcemia as a result of hypoparathyroidism,
developmental and behavioral problems, and psychiatric
disorders in adulthood [6].
If patients undergo in vitro fertilization, preimplan-
tation genetic investigations should be carried out [7].
The incidence of 22q11 deletion is about 48% in
infants with conotruncal congenital cardiac anomaly
[8], and is 13% in patients with a diagnosis of TOF [9].
Careful evaluation of ultrasound examinations carried
out during the second trimester is needed to detect
cardiovascular anomalies. Early prenatal diagnosis is
important for the management of the pregnancy and
delivery, postnatal surgical management, neonatal care,
and decisions regarding cesarean section in cases of fetal
distress. Decision making should involve close cooper-
ation between obstetricians, pediatric cardiologists, and
surgeons.
Fetuses diagnosed prenatally with TOF should un-
dergo genetic investigations to check for 22q11 deletion.
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